An Open-label, Single Dose Study to Determine the Metabolism and Elimination of [14C]E2609 in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 03 Feb 2016
Price : $35 *
At a glance
- Drugs Elenbecestat (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Eisai Co Ltd
- 31 Mar 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
- 11 Feb 2014 Planned End Date changed from 1 Dec 2013 to 1 Feb 2014, as per ClinicalTrials.gov record.
- 22 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.